These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35596030)

  • 1. Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.
    Wojeck BS; Inzucchi SE; Neeland IJ; Mancuso JP; Frederich R; Masiukiewicz U; Cater NB; McGuire DK; Cannon CP; Yaggi HK
    Sleep Breath; 2023 May; 27(2):669-672. PubMed ID: 35596030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F; Cannon CP; Cherney DZI; Masiukiewicz U; Pratley R; Dagogo-Jack S; Frederich R; Charbonnel B; Mancuso J; Shih WJ; Terra SG; Cater NB; Gantz I; McGuire DK;
    Circulation; 2020 Dec; 142(23):2205-2215. PubMed ID: 33026243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
    Cherney DZI; Charbonnel B; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Shih WJ; Frederich R; Maldonado M; Pong A; Cannon CP;
    Diabetologia; 2021 Jun; 64(6):1256-1267. PubMed ID: 33665685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
    Cannon CP; McGuire DK; Pratley R; Dagogo-Jack S; Mancuso J; Huyck S; Charbonnel B; Shih WJ; Gallo S; Masiukiewicz U; Golm G; Cosentino F; Lauring B; Terra SG;
    Am Heart J; 2018 Dec; 206():11-23. PubMed ID: 30290289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
    Cannon CP; Pratley R; Dagogo-Jack S; Mancuso J; Huyck S; Masiukiewicz U; Charbonnel B; Frederich R; Gallo S; Cosentino F; Shih WJ; Gantz I; Terra SG; Cherney DZI; McGuire DK;
    N Engl J Med; 2020 Oct; 383(15):1425-1435. PubMed ID: 32966714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy.
    Lingvay I; Greenberg M; Gallo S; Shi H; Liu J; Gantz I
    Diabetes Obes Metab; 2021 Jul; 23(7):1640-1651. PubMed ID: 33769675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV.
    Dagogo-Jack S; Cannon CP; Cherney DZI; Cosentino F; Liu J; Pong A; Gantz I; Frederich R; Mancuso JP; Pratley RE
    Diabetes Obes Metab; 2022 Jul; 24(7):1245-1254. PubMed ID: 35266296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial?
    Cowart K; Carris NW
    Expert Opin Pharmacother; 2021 Feb; 22(2):163-165. PubMed ID: 32962443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial.
    Dagogo-Jack S; Pratley RE; Cherney DZI; McGuire DK; Cosentino F; Shih WJ; Liu J; Frederich R; Mancuso JP; Raji A; Gantz I
    BMJ Open Diabetes Res Care; 2021 Oct; 9(1):. PubMed ID: 34620621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial.
    Cherney DZI; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Frederich R; Maldonado M; Liu CC; Liu J; Pong A; Cannon CP;
    Clin J Am Soc Nephrol; 2021 Sep; 16(9):1345-1354. PubMed ID: 34497110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial.
    Neeland IJ; Eliasson B; Kasai T; Marx N; Zinman B; Inzucchi SE; Wanner C; Zwiener I; Wojeck BS; Yaggi HK; Johansen OE;
    Diabetes Care; 2020 Dec; 43(12):3007-3015. PubMed ID: 33004464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
    Dagogo-Jack S; Frederich R; Liu J; Cannon CP; Shi H; Cherney DZI; Cosentino F; Masiukiewicz U; Gantz I; Pratley RE
    J Clin Endocrinol Metab; 2023 Jul; 108(8):2042-2051. PubMed ID: 36702781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial.
    Pratley RE; Cannon CP; Cherney DZI; Cosentino F; McGuire DK; Essex MN; Lawrence D; Jones PLS; Liu J; Adamsons I; Dagogo-Jack S
    Lancet Healthy Longev; 2023 Apr; 4(4):e143-e154. PubMed ID: 37003273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV.
    Sridhar VS; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley RE; Cater NB; Noyes Essex M; Mancuso JP; Zhao Y; Cherney DZI
    Diabetes Obes Metab; 2024 Nov; 26(11):5336-5346. PubMed ID: 39219437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin.
    Corbin KD; Dagogo-Jack S; Cannon CP; Cherney DZI; Cosentino F; Frederich R; Liu J; Pong A; Lin J; Cater NB; Pratley RE
    Diabetes Obes Metab; 2023 Mar; 25(3):758-766. PubMed ID: 36394384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
    Cherney DZI; Cosentino F; Pratley RE; Dagogo-Jack S; Frederich R; Maldonado M; Liu J; Pong A; Liu CC; Cannon CP;
    Diabetes Obes Metab; 2022 Jun; 24(6):1114-1122. PubMed ID: 35233908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.
    Ji L; Liu Y; Miao H; Xie Y; Yang M; Wang W; Mu Y; Yan P; Pan S; Lauring B; Liu S; Huyck S; Qiu Y; Terra SG
    Diabetes Obes Metab; 2019 Jun; 21(6):1474-1482. PubMed ID: 30830724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV.
    Budoff MJ; Davis TME; Palmer AG; Frederich R; Lawrence DE; Liu J; Gantz I; Derosa G
    Diabetes Ther; 2021 May; 12(5):1279-1297. PubMed ID: 33721213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV.
    Strojek K; Pandey AS; Dell V; Sisson M; Wang S; Huyck S; Liu J; Gantz I
    Diabetes Ther; 2021 Apr; 12(4):1175-1192. PubMed ID: 33694093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
    Segar MW; Kolkailah AA; Frederich R; Pong A; Cannon CP; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley RE; Liu CC; Maldonado M; Liu J; Cater NB; Pandey A; Cherney DZI
    Diabetes Obes Metab; 2022 Sep; 24(9):1829-1839. PubMed ID: 35603908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.